Scholar Rock Holding Corporation
SRRK
Rank in Stocks
#3482
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Share Price
$40.54
Last synced: 2026-10-19
Market Cap
$4.94B
Change (1 day)
1.59%
Change (1 year)
45.19%
Country
US
Trade Scholar Rock Holding Corporation (SRRK)
Category
Healthcare
Earnings for Scholar Rock Holding Corporation (SRRK)
Earnings in Jun 2026 TTM: $-408.59M
According to Scholar Rock Holding Corporation latest financial reports the company's current earnings are $-408.59M. In 2023 the company made an earning of $-165.79M, a decrease compared to its 2022 earnings that were of $-134.50M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Scholar Rock Holding Corporation from 2016 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-408.59M | 65.90% |
| 2024 | $-246.29M | 48.56% |
| 2023 | $-165.79M | 23.26% |
| 2022 | $-134.50M | 2.05% |
| 2021 | $-131.80M | 52.40% |
| 2020 | $-86.48M | 69.57% |
| 2019 | $-51.00M | 3.39% |
| 2018 | $-49.33M | 97.34% |
| 2017 | $-25.00M | 54.22% |
| 2016 | $-16.21M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -1,391.00% |
US
|
|
| $-3.09B | 655.52% |
US
|
|
| $-4.02B | 882.94% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -577.41% |
NL
|
